Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for CVS Health (NYSE:CVS) from Market ...

"The stock remains at a discounted level versus historical ranges," Cherny said. "The peer set may offer growth-adjusted valuation that are also appealing, but for CVS, it is closer to the end of its ...

CVS Health is seeing signs of stabilization in key business areas, prompting Leerink Partners to upgrade the stock from Market Perform to Outperform and raise its price target to $75 per share in a ...

Leerink Partners analyst shifted the rating for Genmab A/S (NASDAQ:GMAB) stock from Market Perform to Outperform, maintaining a price target (PT) of $27.00. The upgrade reflects a positive long-term ...

Leerink downgraded 10x Genomics (TXG) to Market Perform from Outperform with a price target of $12, down from $25. Despite having the market ...

Leerink analyst Jonathan Chang upgraded Genmab (GMAB) to Outperform from Market Perform with a $27 price target, citing a longer-term view ...

Investment analysts at Leerink Partnrs reduced their FY2028 earnings per share estimates for shares of Inspire Medical Systems in a report released on Tuesday, February 11th. Leerink Partnrs analyst M ...

Stock analysts at Leerink Partnrs reduced their FY2024 EPS estimates for shares of United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects ...

U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...

Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF following the termination of Eli Lilly (NYSE:LLY)'s study. However ...